Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Change in Receivables (2021 - 2023)

Acro Biomedical (ACBM) has 3 years of Change in Receivables data on record, last reported at -$18500.0 in Q3 2023.

  • For Q3 2023, Change in Receivables rose 97.01% year-over-year to -$18500.0; the TTM value through Jun 2024 reached -$18500.0, up 95.36%, while the annual FY2023 figure was -$158500.0, 491.36% down from the prior year.
  • Change in Receivables reached -$18500.0 in Q3 2023 per ACBM's latest filing, up from -$110000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $599000.0 in Q2 2022 and bottomed at -$619000.0 in Q3 2022.
  • Average Change in Receivables over 3 years is -$89500.0, with a median of -$70000.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: soared 160.2% in 2022, then plummeted 118.36% in 2023.
  • A 3-year view of Change in Receivables shows it stood at -$598000.0 in 2021, then skyrocketed by 160.2% to $360000.0 in 2022, then tumbled by 105.14% to -$18500.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$18500.0 in Q3 2023, -$110000.0 in Q2 2023, and -$30000.0 in Q1 2023.